Galectin Therapeutics Inc
(STU:PHPN)
€
3.68
-1 (-21.37%)
Market Cap: 244.33 Mil
Enterprise Value: 353.05 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 27/100 Galectin Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023 / 02:30PM GMT
Release Date Price:
€1.47
(-6.37%)
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Great. Well, we'll get started. Our next presenting company is Galectin Therapeutics. And joining us is the President and CEO, Joel Lewis; as well as Pol Boudes, the Chief Commercial Officer -- sorry, Medical Officer.
Joel Lewis
Galectin Therapeutics Inc. - CEO & President
He can be the Chief Commercial Officer too.
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Good, good. Welcome, both of you.
Joel Lewis
Galectin Therapeutics Inc. - CEO & President
Thank you.
Pol Boudes
Galectin Therapeutics Inc. - Chief Medical Officer
Welcome.
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
So I wanted to start if you could just briefly introduce the company and its strategy.
Joel Lewis
Galectin Therapeutics Inc. - CEO & President
Sure. First of all, thank you to Ed and H.C.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot